Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies.
Sign Up to like & getrecommendations! Published in 2019 at "Lung cancer"
DOI: 10.1016/j.lungcan.2019.09.015
Abstract: OBJECTIVES There are limited treatment options for patients with thymic malignancies. Here we present data supporting treatment with single agent amrubicin, a third generation anthracycline and topoisomerase II inhibitor. MATERIALS AND METHODS This was a… read more here.
Keywords: agent; single agent; thymic malignancies; amrubicin patients ... See more keywords
Efficacy and Safety of Amrubicin Monotherapy After Chemoradiotherapy in Patients With Relapsed Limited Disease Small-cell Lung Cancer
Sign Up to like & getrecommendations! Published in 2025 at "AntiCancer Research"
DOI: 10.21873/anticanres.17461
Abstract: Background/Aim: Amrubicin is recognized as a second-line treatment for refractory small-cell lung cancer (SCLC) and is administered immediately after chemotherapy; however, it has not been evaluated in patients with recurrent SCLC following chemoradiotherapy (CRT). This… read more here.
Keywords: amrubicin; amrubicin monotherapy; efficacy; crt ... See more keywords